| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quantitative Trait Loci | 15 | 2022 | 632 | 1.770 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 1766 | 1.580 |
Why?
|
| Lung Neoplasms | 28 | 2014 | 2384 | 1.490 |
Why?
|
| Chromosome Mapping | 9 | 2022 | 1080 | 1.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2014 | 1144 | 1.230 |
Why?
|
| Animals, Outbred Strains | 2 | 2018 | 17 | 1.050 |
Why?
|
| Behavior, Animal | 6 | 2016 | 394 | 0.990 |
Why?
|
| Fear | 7 | 2015 | 88 | 0.920 |
Why?
|
| Alcoholism | 2 | 2022 | 191 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2010 | 2605 | 0.650 |
Why?
|
| Crosses, Genetic | 6 | 2014 | 171 | 0.590 |
Why?
|
| Organ Size | 2 | 2018 | 376 | 0.540 |
Why?
|
| Testis | 1 | 2018 | 152 | 0.530 |
Why?
|
| Genetics, Behavioral | 2 | 2013 | 22 | 0.490 |
Why?
|
| Genetic Markers | 2 | 2016 | 477 | 0.470 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 2059 | 0.460 |
Why?
|
| Mice | 19 | 2022 | 12525 | 0.450 |
Why?
|
| Motor Activity | 4 | 2015 | 332 | 0.440 |
Why?
|
| Genotype | 6 | 2018 | 1883 | 0.430 |
Why?
|
| Anxiety | 2 | 2014 | 339 | 0.430 |
Why?
|
| Chromosomes | 1 | 2014 | 96 | 0.420 |
Why?
|
| Phenotype | 9 | 2022 | 2575 | 0.410 |
Why?
|
| Precision Medicine | 3 | 2014 | 456 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 4 | 2014 | 117 | 0.380 |
Why?
|
| Animals | 25 | 2022 | 28901 | 0.380 |
Why?
|
| Alleles | 2 | 2017 | 1157 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2022 | 2495 | 0.370 |
Why?
|
| Models, Animal | 1 | 2013 | 287 | 0.360 |
Why?
|
| Conditioning, Classical | 5 | 2015 | 38 | 0.350 |
Why?
|
| Body Weight | 2 | 2019 | 460 | 0.350 |
Why?
|
| Methamphetamine | 2 | 2015 | 104 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 547 | 0.330 |
Why?
|
| Neoplasm Staging | 13 | 2011 | 2042 | 0.320 |
Why?
|
| Male | 38 | 2022 | 45792 | 0.320 |
Why?
|
| Carboplatin | 7 | 2010 | 328 | 0.320 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 2385 | 0.300 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 451 | 0.290 |
Why?
|
| Early Detection of Cancer | 3 | 2013 | 484 | 0.280 |
Why?
|
| Mice, Inbred DBA | 6 | 2014 | 149 | 0.270 |
Why?
|
| Quality of Life | 8 | 2008 | 1816 | 0.270 |
Why?
|
| Mice, Inbred Strains | 5 | 2014 | 297 | 0.250 |
Why?
|
| Health Status | 3 | 2008 | 386 | 0.250 |
Why?
|
| Computational Biology | 3 | 2018 | 587 | 0.240 |
Why?
|
| Deoxycytidine | 3 | 2007 | 216 | 0.230 |
Why?
|
| Female | 32 | 2019 | 49980 | 0.220 |
Why?
|
| Basolateral Nuclear Complex | 2 | 2015 | 3 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 9 | 2015 | 3483 | 0.210 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 481 | 0.210 |
Why?
|
| Humans | 44 | 2019 | 95992 | 0.200 |
Why?
|
| Databases, Genetic | 2 | 2017 | 283 | 0.200 |
Why?
|
| Survival Analysis | 9 | 2010 | 1541 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 198 | 0.180 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 129 | 0.180 |
Why?
|
| Pedigree | 2 | 2014 | 978 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 1191 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 307 | 0.180 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.170 |
Why?
|
| Central Nervous System Stimulants | 3 | 2015 | 235 | 0.170 |
Why?
|
| Quinazolines | 2 | 2006 | 216 | 0.170 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 66 | 0.160 |
Why?
|
| Neoplasms | 5 | 2014 | 3242 | 0.160 |
Why?
|
| Nanotechnology | 1 | 2011 | 73 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2011 | 9228 | 0.160 |
Why?
|
| Aged | 17 | 2019 | 20927 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 677 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 45 | 0.150 |
Why?
|
| Muscle Development | 1 | 2019 | 45 | 0.150 |
Why?
|
| Ethanol | 1 | 2022 | 273 | 0.150 |
Why?
|
| Body Composition | 1 | 2019 | 75 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 120 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1425 | 0.150 |
Why?
|
| ErbB Receptors | 3 | 2011 | 513 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 190 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2011 | 1014 | 0.140 |
Why?
|
| Glycoproteins | 1 | 2019 | 231 | 0.140 |
Why?
|
| Middle Aged | 19 | 2019 | 28299 | 0.140 |
Why?
|
| Aged, 80 and over | 10 | 2010 | 7224 | 0.140 |
Why?
|
| Inbreeding | 3 | 2013 | 48 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2007 | 104 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2011 | 408 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 644 | 0.130 |
Why?
|
| Genetic Linkage | 1 | 2018 | 620 | 0.120 |
Why?
|
| Sulindac | 1 | 2006 | 8 | 0.120 |
Why?
|
| Electroshock | 2 | 2015 | 18 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 99 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 273 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 857 | 0.120 |
Why?
|
| Dendritic Spines | 1 | 2015 | 16 | 0.120 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2015 | 21 | 0.120 |
Why?
|
| Adult | 16 | 2019 | 28636 | 0.120 |
Why?
|
| Camptothecin | 2 | 2007 | 202 | 0.120 |
Why?
|
| Dopaminergic Neurons | 1 | 2015 | 30 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2007 | 1166 | 0.120 |
Why?
|
| Disease Progression | 5 | 2008 | 1561 | 0.120 |
Why?
|
| Spectrum Analysis | 2 | 2011 | 121 | 0.110 |
Why?
|
| Face | 1 | 2015 | 114 | 0.110 |
Why?
|
| Paclitaxel | 6 | 2007 | 488 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2013 | 984 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2018 | 439 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1670 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3922 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 47 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 86 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 89 | 0.100 |
Why?
|
| Hybridization, Genetic | 1 | 2014 | 107 | 0.100 |
Why?
|
| Skull | 1 | 2015 | 273 | 0.100 |
Why?
|
| Breeding | 1 | 2013 | 42 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 68 | 0.100 |
Why?
|
| Zinc Fingers | 1 | 2013 | 60 | 0.100 |
Why?
|
| Neutropenia | 2 | 2009 | 211 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2014 | 3581 | 0.100 |
Why?
|
| Goals | 1 | 2013 | 68 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 234 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 186 | 0.100 |
Why?
|
| Melanoma | 2 | 2004 | 495 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 506 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 125 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2014 | 302 | 0.090 |
Why?
|
| Receptors, Cannabinoid | 1 | 2012 | 5 | 0.090 |
Why?
|
| Prognosis | 7 | 2011 | 3993 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2012 | 83 | 0.090 |
Why?
|
| Protons | 1 | 2002 | 104 | 0.090 |
Why?
|
| Survival Rate | 6 | 2011 | 1978 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2012 | 131 | 0.090 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 131 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 1424 | 0.090 |
Why?
|
| Indazoles | 1 | 2011 | 61 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 77 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2012 | 252 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2011 | 235 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 99 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 325 | 0.080 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 71 | 0.080 |
Why?
|
| Cues | 1 | 2012 | 189 | 0.080 |
Why?
|
| Rats | 2 | 2013 | 4155 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 313 | 0.080 |
Why?
|
| Skin Diseases, Infectious | 1 | 2009 | 12 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2004 | 1741 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 930 | 0.080 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 5 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 1464 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 2009 | 38 | 0.080 |
Why?
|
| Reward | 1 | 2011 | 209 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 621 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 1021 | 0.070 |
Why?
|
| Pemetrexed | 1 | 2009 | 76 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 1195 | 0.070 |
Why?
|
| Glutamates | 1 | 2009 | 90 | 0.070 |
Why?
|
| Salvage Therapy | 3 | 2011 | 238 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2002 | 848 | 0.070 |
Why?
|
| Carcinoma | 1 | 2001 | 444 | 0.070 |
Why?
|
| Guanine | 1 | 2009 | 207 | 0.070 |
Why?
|
| Fatigue | 1 | 2009 | 186 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 188 | 0.070 |
Why?
|
| Anemia | 1 | 2009 | 136 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2009 | 275 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1267 | 0.070 |
Why?
|
| Palliative Care | 1 | 1999 | 271 | 0.060 |
Why?
|
| Adenoma | 1 | 2009 | 260 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 890 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 514 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 463 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2008 | 517 | 0.060 |
Why?
|
| Proteins | 1 | 2012 | 816 | 0.060 |
Why?
|
| Skin | 1 | 2009 | 604 | 0.060 |
Why?
|
| Brain | 1 | 2016 | 2479 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2008 | 819 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 272 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 587 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1087 | 0.050 |
Why?
|
| Neurons | 1 | 2013 | 1654 | 0.050 |
Why?
|
| Mutation | 3 | 2011 | 4374 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 150 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2015 | 2088 | 0.050 |
Why?
|
| Breath Tests | 1 | 2013 | 58 | 0.050 |
Why?
|
| Taxoids | 2 | 2008 | 129 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 355 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2011 | 2498 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2007 | 935 | 0.050 |
Why?
|
| Peptide Synthases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Age Factors | 3 | 2012 | 1959 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 611 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 1130 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.040 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2885 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 73 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2008 | 4690 | 0.040 |
Why?
|
| Remission Induction | 2 | 2004 | 750 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 134 | 0.040 |
Why?
|
| Prevalence | 2 | 2009 | 1355 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 202 | 0.040 |
Why?
|
| Cetuximab | 1 | 2010 | 119 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2005 | 721 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2008 | 34 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2004 | 315 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2007 | 91 | 0.030 |
Why?
|
| Risk | 1 | 2008 | 666 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2008 | 239 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2015 | 21 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 209 | 0.030 |
Why?
|
| Time Factors | 2 | 2006 | 5593 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 270 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 232 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2009 | 10307 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1962 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 766 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2007 | 936 | 0.030 |
Why?
|
| Lod Score | 1 | 2014 | 153 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 233 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2014 | 38 | 0.030 |
Why?
|
| Vomiting | 1 | 2006 | 201 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 420 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 307 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2004 | 340 | 0.030 |
Why?
|
| Hindlimb | 1 | 2014 | 97 | 0.030 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 5 | 0.030 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2013 | 11 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1827 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2013 | 44 | 0.030 |
Why?
|
| Corticosterone | 1 | 2013 | 35 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 64 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 81 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2777 | 0.020 |
Why?
|
| Random Allocation | 1 | 2013 | 321 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 2474 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1018 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1966 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 703 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2534 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 491 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 49 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1982 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 708 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2001 | 41 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 60 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 34 | 0.020 |
Why?
|
| Genome | 1 | 2014 | 407 | 0.020 |
Why?
|
| Craniotomy | 1 | 2001 | 97 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 360 | 0.020 |
Why?
|
| Locomotion | 1 | 2012 | 146 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1267 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 159 | 0.020 |
Why?
|
| Skin Diseases, Viral | 1 | 2009 | 3 | 0.020 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2009 | 9 | 0.020 |
Why?
|
| Dermatomycoses | 1 | 2009 | 11 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 686 | 0.020 |
Why?
|
| Leukopenia | 1 | 2009 | 65 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 21 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 98 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2860 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 126 | 0.020 |
Why?
|
| Duodenum | 1 | 2009 | 112 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2009 | 181 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 1079 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 7034 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 2090 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2001 | 318 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 9878 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 206 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2001 | 476 | 0.020 |
Why?
|
| Vinblastine | 1 | 2007 | 85 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3040 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1999 | 325 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 99 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2160 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 651 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1618 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2042 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 1210 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2611 | 0.010 |
Why?
|
| Colon | 1 | 2009 | 540 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 710 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 3359 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 364 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 3969 | 0.010 |
Why?
|
| United States | 1 | 2008 | 7785 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 193 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 221 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 824 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 591 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 454 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 897 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 476 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 997 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 218 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7621 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 3155 | 0.010 |
Why?
|